Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BNZ-1 |
Synonyms | |
Therapy Description |
BNZ-1 is a peptide that selectively inhibits IL-2, IL-15, and IL-9 signaling, which may lead to anti-tumor activity (Blood 2017 130(Suppl 1):695, PMID: 31465127). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BNZ-1 | BNZ132-1-40 | BNZ-1 is a peptide that selectively inhibits IL-2, IL-15, and IL-9 signaling, which may lead to anti-tumor activity (Blood 2017 130(Suppl 1):695, PMID: 31465127). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03239392 | Phase Ib/II | BNZ-1 | A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL | Completed | USA | 0 |